SWOG clinical trial number
S1316
Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
Closed
Phase
Accrual
100%
Abbreviated Title
Surgery vs Non-Surgical Management for MBO
Status Notes
Re-Activation - Effective 6/1/18
Activated
03/09/2015
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Cancer Survivorship
Gastrointestinal Cancer
Treatment
Surgery
Non-surgical management
Other Study Materials
Eligibility Criteria Expand/Collapse
Must have malignant bowel obstruction (MBO); must have MBO due to an intra-abdominal primary cancer; must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems; a member of the surgical team must indicate equipoise for the benefit of the surgical treatment for MBO; pts must not have signs of bowel perforation or "acute" abdomen as evidenced by free air on radiologic imaging or peritonitis on a physical exam within 2 days prior to reg; must be registered within 3 days after surgical consult for MBO and prior to any treatment for MBO; Zubrod PS 0-2 within 7 days prior to reg; must plan to collect serum albumin after admission, but prior to treatment; must be able to complete study questionnaires in English; must be >/= 18 years old.
Publication Information Expand/Collapse
2023
PMid: PMID37541263 | PMC number: PMC10530384
2020
PMid: PMID31122027 | PMC number: PMC6868288
Successful implementation of a novel trial design in a palliative care population
2015
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
71%
Open
Phase
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
27%
Open
Phase